banda transcan 2 2016ul

Title:
Translational Research in Peripheral T-Cell Lymphomas: from characterization to novel targets

Project Coordinator:
Lorenz Truemper (Germany), University Medical Center of Goettingen, Department of Hematology & Oncology, Goettingen

Project Partners:
Reiner Siebert (Germany), Ulm University & Ulm University Medical Center, Dept. of Human Genetics, Ulm
Daphne de Jong (Netherlands), VU University Medical Center, Department of Pathology, Amsterdam
Philipp Staber (Austria), Medical University of Vienna, Department of Medicine I, Division of Hematology & Hemostaseology, Vienna
Olivier Tournilhac (France), Clermont-Ferrand University Hospital, Dept.of Hematology, Clermont-Ferrand

Project Abstract:
Background. Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of rare lymphoid malignancies. With current treatment options, the majority of patients do not achieve remission or experience relapse after completion of therapy, generally with dismal outcome [1-4]. Mechanisms of progression and relapse remain elusive and predictive biomarkers do not exist, precluding clinical progress.
Hypothesis. We hypothesize that utilizing a unique collection of clinically annotated samples from multiple European trials and registries for detailed pathologic assessment and comprehensive characterization of the (epi-) genetic landscape will unravel pivotal mechanisms determining the unique biology and clinical behavior of PTCL.
Aims. Aim 1: Collect a clinically annotated, comprehensively characterized and centrally reviewed sample collection of PTCL. Aim 2: Perform a comprehensive genetic and epigenetic characterization and identify prognostic (epi-) genetic biomarkers. Aim 3: Identify molecular targets and develop novel therapeutic strategies.
Methods. This study will be based on biopsy samples of patients treated in prospective European clinical trials and from population-based cohorts that are collected via the national pathology reference centers. Whole exome sequencing, genome-wide DNA methylation profiling and targeted sequencing results will be correlated with clinical parameters, including progression and outcome. (Epi-) Genetic alterations will be addressed with drug screening assays in pre-clinical models and ex vivo in primary PTCL samples.
Expected results & impact. This study will provide a comprehensively characterized catalogue of clinically annotated samples across the major subtypes of PTCL. The integrated analysis of (epi-) genetic alterations will elucidate pathogenic mechanisms and the correlation with clinical endpoints will provide insight in prognostic biomarkers. Finally, novel therapeutic strategies will be explored on the basis of these data.

 

(Project funded under JTC 2017)


TRANSCAN-2 News


Fourth Joint Transnational Call 2017 (JTC 2017)

on: Translational Research on Rare Cancers

12 projects selected for funding

visit the page

Newsletters

Newsletter 7, October 2018

Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, December 2017
Newsletter 3, September 2017
Newsletter 2, April 2017
Newsletter 1, December 2016

To subscribe to TRANSCAN-2 newsletter mailing list please send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.